

MEDICURE INC  
Form 6-K  
December 20, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **December 2017**

Commission File Number: **001-31995**

**MEDICURE INC.**

(Translation of registrant's name into English)

**2-1250 Waverley Street**

**Winnipeg, MB Canada R3T 6C6**

(Address of principal executive offices)

Edgar Filing: MEDICURE INC - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
8a72\_\_\_\_\_.

**EXHIBIT LIST**

Exhibit Title

99.1 News Release Dated December 19, 2017 - Medicare Announces FDA Approval Received for Prexxartan®

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Medicare Inc.**  
(Registrant)

Date: December 19, 2017 By: /s/ Dr. Albert D. Friesen  
Dr. Albert D. Friesen  
Title: President & CEO